The mechanism underlying angiogenesis in liver cancer involves METTL3-mediated m6A modification of FOXO3 mRNA to increase its stability through a YTHDF1-dependent mechanism, which ultimately enhances sorafenib resistance of HCC (148). Here, METTL3 is linked to hepatocellular carcinoma.